UTHR Stock United Therapeutics Corporation

$554.73
1d-0.78%5d-6.16%1m-1.55%ytd+13.85%
At close · Nov 20, 4:00 PM ET
After hours $554.73 +0% · Nov 20, 6:11 PM ET
52w low $455.6362% of range$614.23 52w high
Price

Today’s call · UTHR

All live ideas →

Checks are split 3–3 — no clear lean

UTHR is in an uptrend, momentum soft. $559.93 is the level overhead; $550 the first support below.

No open idea.From $554.73 the reward-to-risk to $559.93 against $550 is 1.1 — below the 3:1 bar.
What would create one:
  • A close above $559.93 on rising volume (breakout).
  • A pullback to $550 that holds (entry near support).
Alert me at a level

The brief

Price vs 50-day · abovePrice vs 200-day · above50d vs 200d avg · aboveMACD · bearishRSI momentum · 425-day tape · -6.2%
signalUTHR’s 50-day average is above the 200-day — long-term trend alignment is bullish.
levelPrice is 0.94% from resistance $559.93 — watch for a break or rejection.
levelFirst support $550.0 is 0.85% below.
newsUnited Therapeutics evp Mahon sells $4.69M in company stock By Investing.com
newsChairperson & CEO Martine Rothblatt sells $3.13M United Therapeutics stock By Investing.com
All readings
TrendUptrend · above 50-day & 200-day
MomentumRSI 42.0 · MACD bearish
Trend strengthADX 17.6 · weak or range
Location+0.9% vs 50-day MA
52-week range-9% from high · +19% from low
VolatilityATR 19.67 · ~3.5%/day
RSI 14
42.0
MACD
3.99
ADX 14
17.6
ATR 14
19.67
SMA 50
$550
SMA 200
$539.85

Levels that matter

$559.93swing zone · 5×+0.9%
$583.09swing zone · 2×+5.1%
$596.25swing zone · 2×+7.5%
$550round−0.8%
$539.85sma 200−2.7%
$535.55swing zone · 6×−3.5%

Compare with…

Latest news

1 / 2
Analyst overview · Nov 16 · updated Nov 19

United Therapeutics (UTHR) stock analysis, November 16, 2026: bullish outlook on short‑term upside

Update, November 19, 2026

Since the November 16 report, United Therapeutics slipped to $555.66, a 3.76% drop on the day and a 6.35% decline over the past five days, while the S&P 500 fell 0.23% and the XLV health‑care ETF slid 1.86% in the same period, keeping the stock’s relative under‑performance modest but still negative. The picture holds: the daily price remains below the swing‑zone breakout level of 559.93 and above the primary support at $550, while volume is still well under its 20‑day average, so the breakout criteria have not been met.

The key levels from the prior assessment have not shifted: the upside target at $583.09 (swing zone) and the 52‑week high target at $608.49 remain unchanged, as does the stop at $545.15 based on the rounded $550 minus a quarter of the ATR. The stock stays above its 40‑week average and the 50‑day SMA (548.78), preserving the bullish alignment, but the RSI at 42.4 signals lingering weakness. What would change the picture? A weekly close below the swing‑zone level of 560.76 would trigger a reassessment, as would a decisive move above the breakout threshold on volume above the 20‑day average.

United Therapeutics (UTHR) closed at $591.2 on November 13, holding above its swing‑zone support and still under the 52‑week high of $608.5. The daily trend follows a weekly uptrend, and the stock has outperformed both the S&P 500 and the XLV health‑care ETF over the past 50 days. The balance of evidence points to a bullish short‑term outlook, with a high conviction that the next move will be to the upside breakout level of $600.

Why it matters

The most recent market event was United Therapeutics’ earnings release on November 4, which confirmed the company’s ongoing product pipeline progress and solid revenue growth. The earnings beat was already priced in, as the stock rose 5.2% over the prior five days, outpacing the sector’s 2.2% gain and the broader market’s 2.6% rise. The move was therefore driven more by the stock’s relative strength than by sector momentum.

Relative performance metrics reinforce that narrative: UTHR’s 5‑day outperformance versus the S&P 500 was 10.4% and versus XLV was 1.1%, indicating that the stock’s rally is not merely a reflection of a health‑care rally but a distinct, stock‑specific thrust. The price is still above its 40‑week average, confirming that the long‑term trend remains intact.

Analyst consensus remains a “buy” with a mean price target of $687, though the current price sits 14% below that target. The spread between the low ($390) and high ($850) targets is wide, suggesting divergent views on upside potential, but the consensus still leans strongly positive.

Debate in the market centers on whether the recent rally is sustainable. One side argues that the stock’s momentum is fragile because volume on the last session was 12% below the 20‑day average, implying limited buying pressure. The opposing view points to the daily close staying above the swing‑zone support at $583.1 and the RSI at 58, which still leaves room for further upside before overbought conditions emerge. Both arguments rely on the same data points, and the weight of evidence favors the bullish side because the structural support remains intact and the weekly trend is still upward.

What the evidence says

On the long‑term horizon, the thesis that UTHR is in an uptrend remains intact. The price is above both its 50‑day ($542.6) and 200‑day ($537.5) moving averages, and it sits 2.85% below the 52‑week high, leaving a comfortable margin for further gains. The swing‑zone support at $583.1 is holding, and the stock has not broken below the trend‑ending level of $560.8.

Looking ahead to the next two to six weeks, the balance of evidence leans positive with a high conviction. The assessment lists three of four conviction points: daily trend alignment with the weekly uptrend, a 10.4% outperformance versus the S&P 500 over 50 days, and a 1.1% outperformance versus XLV. The breakout math calls for a daily close above $600 on volume above the 20‑day average, which would trigger a target at the 52‑week high of $608.5. The reward‑to‑risk ratio is modest at 0.4, and the math does not meet a 3‑to‑1 payoff, meaning the upside must be larger to justify the risk.

The strongest case against a near‑term upside is the recent dip in volume, now 12% below the 20‑day average, which could limit the strength of any breakout. However, the price has already held above the swing‑zone support and the stop is set at $578.7, providing a buffer that mitigates the volume concern.

Levels that matter

The structure holds above the swing‑zone support at $583.1, a level derived from recent price action and the swing‑zone definition. A break below $560.8 would signal the end of the weekly uptrend, as that level marks the lower boundary of the swing‑zone where a weekly close below would change the picture.

The breakout level is a daily close above $600 on volume above the 20‑day average. If achieved, the math points to a target at the 52‑week high of $608.5, with a reward‑to‑risk of 0.4. The stop is placed at $578.7, based on the swing‑zone high minus a quarter of the 14‑day ATR ($17.55). Because the reward‑to‑risk does not reach 3‑to‑1, a price move to roughly $630 would be needed to achieve that ratio.

What would change the picture

A weekly close below $560.8 would alter the current bullish outlook, as that level is the rule for a picture change in the swing‑zone. Additionally, a significant shift in earnings guidance or a major regulatory setback would also overturn the present assessment.

What to watch

  • Next earnings release on November 4 – focus on the earnings per share figure and any guidance change.
  • Sector catalysts such as FDA approvals or major health‑care policy announcements that could move XLV and, by extension, UTHR.
  • Valuation versus consensus: the stock trades 14% below the mean analyst target of $687, indicating room for upside if fundamentals remain solid.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.